scholarly journals NCMP-19. SIDE EFFECTS FROM CHEMOTHERAPY VERSUS SYMPTOMS FROM COVID-19 INFECTION

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii126-ii127
Author(s):  
Senxi Du ◽  
Maya Hrachova ◽  
Xiao-Tang Kong
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Clinical History ◽  
Nausea And Vomiting ◽  
Medical Attention ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Ocular Lymphoma ◽  
Dose Methotrexate ◽  
History Of

Abstract INTRODUCTION Adverse effects from chemotherapy such as high dose methotrexate (HD-MTX) are seen during and after chemotherapy. During this coronavirus disease 2019 (COVID-19) pandemic period, COVID-19 infection symptoms following chemotherapy due to immune compromise could mimic chemotherapy associated side effects. Differentiation on time is needed for correct management. CASE REPORT A 50-year old male with clinical history of ocular lymphoma underwent HD-MTX therapy. Before admission, his routine COVID-19 test was negative. After receiving HD-MTX, he developed fatigue, nausea and vomiting. The symptoms resolved before discharge. Next day after discharge, he developed diarrhea, fatigue, subjective fever and feeling cold. His temperature was normal. His symptoms have been persistent for 4-5 days and have resolved gradually and spontaneously. Family members have had no symptoms. The patient denies COVID-19 contact history. The above symptoms were considered adverse effects from chemotherapy. The patient did not seek medical attention. Prior to admission for next cycle of HD-MTX, COVID-19 test was found positive. Chemotherapy was on hold. The patient started home quarantine. The patient has been doing well and practiced COVID-19 infection precaution at home. DISCUSSION The fatigue, nausea and vomiting during HD-MTX treatment are adverse effects from chemotherapy while the diarrhea, fatigue, subjective fever and chills developed after discharge are symptoms of COVID-19 infection. Our case highlights the importance of keeping in mind and differentiating between side effects from chemotherapy and symptoms of COVID-19 viral infection in cancer patients who receive chemotherapy.

scholarly journals PC3 - 130 A Meta-Analysis on the use of High-Dose Methotrexate Only Versus Combination Chemotherapy for the Treatment of Newly-Diagnosed Patients with Primary CNS Lymphoma

2016 ◽  
Vol 43 (S4) ◽  
pp. S20-S21
Author(s):  
M.C. Concepcion Sales
Keyword(s):  
Side Effects ◽  
Disease Progression ◽  
Combination Chemotherapy ◽  
Primary Cns Lymphoma ◽  
Complete Response ◽  
Cns Lymphoma ◽  
High Dose ◽  
Cochrane Central Register ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

Primary CNS Lymphoma (PCNSL) is an unusual extranodal form of Non-Hodgkin’s Lymphoma with a locally aggressive course but a rare tendency to disseminate systemically. There are various modalities available for the treatment of PCNSL which include chemotherapy, radiotherapy, surgery and immunotherapy. The effectiveness of adding another anti-neoplastic agent to HD-MTX have been optimized in small scale studies yet the “ perfect combination” has yet to be elucidated Objectives: This study aims to 1) compare the response to treatment of monotherapy with high-dose Methotrexate (HD-MTX) versus HD-MTX and an additional anti-neoplastic agent by evaluating complete response, partial response, stable disease and disease progression and 2) to compare the hematologic and non-hematologic side effects among patients subjected to monotherapy vs combination chemotherapy. Methodology: Journals from Medline, EMBASE, Cochrane Central Register of Control Trials (CENTRAL) and other relevant websites (www.clinicaltrials.org) without any restrictions in the year, language and status of publication were searched. Literatures cited by eligible studies and systemic reviews were also checked to identify useful articles. The following Medical Subject Headings (MeSH) were used: ‘primary CNS lymphoma’, ‘treatment’, ‘chemotherapy’ and ‘randomized control trial’. Statistical analysis was performed using the RevMan software version 5.1. Odds ratio (OR) and 95 % confidence interval (95% CI) were used as summary statistics. Results and Conclusion: The use of high-dose methotrexate and another anti-neoplastic agent showed benefit in terms of achieving complete response and delaying disease progression among patients diagnosed with PCNSL. However, the risks of hematologic toxicities such as anemia, neutropenia, thrombocytopenia and infection was higher in patients treated with the combination chemotherapy. Significant non-hematologic side effects such as mucositis was also observed in patients receiving an add-on to high dose methotrexate.

Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate

2015 ◽  
Vol 24 (3) ◽  
pp. 1365-1371 ◽  
Author(s):  
Helen Vol ◽  
Jacqueline Flank ◽  
Sara R. Lavoratore ◽  
Paul C. Nathan ◽  
Tracey Taylor ◽  
...  
Keyword(s):  
Nausea And Vomiting ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

HEMOSTATIC SIDE EFFECTS OF HIGH-DOSE METHOTREXATE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

2004 ◽  
Vol 21 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Tunc Fisgin ◽  
Nese Yarali ◽  
Abdurrahman Kara ◽  
Ceyhun Bozkurt ◽  
Dilek Birgen ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Side Effects ◽  
Lymphoblastic Leukemia ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

scholarly journals Hematological, hepatic, and renal adverse effects of high dose methotrexate injection (50 mg weekly) in severe psoriasis cases

2019 ◽  
Author(s):  
Adissa Tiara Yulinvia ◽  
Prasta Bayu Putra ◽  
Niken Trisnowati ◽  
Sunardi Radiono
Keyword(s):  
Adverse Effects ◽  
Laboratory Data ◽  
Severe Psoriasis ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Laboratory Findings ◽  
Dose Methotrexate ◽  
Medical Facilities ◽  
Close Supervision ◽  
High Level

Ten to 30 mg weekly methotrexate (MTX) has long been used as a treatment for severe, recalcitrant psoriasis. However, some patients do not improve with those dose and there has been oral methotrexate scarcity period in Indonesia since 2015. This is the first study to evaluate the safety profile of high dose (50 mg weekly) MTX injection in severe psoriasis cases at Sardjito hospital, Yogyakarta. We conducted a retrospective adverse effects evaluation from demographic and laboratory data of 23 severe psoriasis patients who had received six weekly intramuscular injections of MTX. For the results, five (21.70%) patients developed hematological adverse effects, four (17.30%) patients developed hepatic adverse effects, and three (13.05%) patients developed renal adverse effects. Majority of the abnormal laboratory findings in this study were mild and transient. High dose MTX injection appears to be safe for severe psoriasis if proper patient baseline condition assessment was taken before starting therapy, all contraindications have been excluded, and is used under close supervision at high level medical facilities.

Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate

2012 ◽  
Vol 59 (5) ◽  
pp. 870-873 ◽  
Author(s):  
Sambavy Nadaraja ◽  
Aissata Diop Mamoudou ◽  
Harald Thomassen ◽  
Peder Skov Wehner ◽  
Steen Rosthoej ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Nausea And Vomiting ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate
Sign in / Sign up

Export Citation Format

Share Document